Table 2.
Clinical characterization of peritonsillar and DNI in pediatric patients admitted, according to infection subtype, from 2011 to 2016.
| Type of infection | Patients, No. (%) (n = 98) | Side (n = 98) | Age (n = 98, Mean ± SD) | HLS (n = 83, Mean ± SD)a | HLS>5 d (n = 83)a | Antibiotics during hospitalization (n = 83)a |
|---|---|---|---|---|---|---|
| Peritonsillar Abscess | 71 (72.4) | Left-42 Right-27 Bilateral-2 |
12.43 ± 4.91 | 4.43 ± 1.22 | 9 | AC + Clindamycin- 61 Clarithromycin + Clindamycin- 1 AC- 4 Ceftriaxone + Clindamycin- 4 Ceftriaxone + Metronidazole- 1 |
| Parapharyngeal Abscess | 7 (7.1) | Left-2 Right-5 Bilateral- 0 |
10.80 ± 5.02 | 4.20 ± 0.84 | 1 | AC + Clindamycin- 4 Ceftriaxone + Clindamycin- 2 Ceftriaxone- 1 |
| Retropharyngeal Abscess | 4 (4.1) | Left-2 Right-1 Bilateral-1 |
6,00 ± 2.83 | 5.25 ± 1.71 | 3 | AC + Clindamycin- 2 Ceftriaxone + Clindamycin- 1 Clindamycin- 1 |
| Peritonsillar celullitis | 15 (15.3) | Left-8 Right-6 Bilateral- 1 |
10.43 ± 4.47 | 3.80 ± 2.51 | 1 | AC + Clindamycin- 14 AC- 1 |
| Retropharyngeal celullitis | 1 (1.0) | Right | 1 | AC + Clindamycin | ||
| P- value | >0.05 | >0.05 | <0.05 | <0.05 |
DNI: deep neck infection; HLS: hospital length of stay; AC: Amoxicillin-clavulanate.
a
15 patients transfered to the hospital of local residency were excluded.